Program is part of U.S. Government’s ‘Project NextGen’ and provides partial funding for clinical development of a novel monoclonal antibody therapyTARRYTOWN, N.Y., Aug. 22, 2023 Regeneron.
TARRYTOWN, N.Y., Aug. 17, 2023 Regeneron Pharmaceuticals, Inc. today announced that the European Medicines Agency has accepted for review the Marketing Authorization Application for.
TARRYTOWN, N.Y., Aug. 17, 2023 (GLOBE NEWSWIRE) Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA)